5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital

2. 23andMe Holding Co. (NASDAQ:ME)

Euclidean Capital’s Stake Value: $119 million

Percentage of Euclidean Capital’s 13F Portfolio: 27.98%

Number of Hedge Fund Holders: N/A

Euclidean Capital initiated a new position in 23andMe Holding Co. (NASDAQ:ME) in the second quarter of 2021 by purchasing 10.2 million shares. Nevertheless, the stock price bounced back after hitting a 52-weeks low of $8 at the beginning of October, thanks to price target upgrades and positive comments from EMJ Capital founder Eric Jackson.

As of the end of June, Jim Simons’ Euclidean Capital was the leading stakeholder in the company while Eli Casdin’s Casdin Capital was the second-largest hedge fund shareholder.